Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9

Investigational New Drugs

Volumn 14, Issue 2, 1996, Pages 181-191

  Jonkman de Vries, Jantine D ^a   Van Den Bosch, J Jantina Kettenes ^b   Henrar, Roland E C ^c   Bult, Auke ^b   Beijnen, Jos H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EO9; Intermediates in the synthesis; Purity determinations; Quality control

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALCOHOL; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; METHANOL; ORGANIC SOLVENT;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG IMPURITY; DRUG PURITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROMETRY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY;

EID: 0029823237     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00210789     Document Type: Article

References (17)

1. Winograd B, Lobbezoo MW, Double JA, Fiebig HH, Lelieveld P, Workman P, Pinedo HM: Preclinical antitumor profile of EO9, a novel bioreductive alkylating indoloquinone derivative. Proc Am Assoc Cancer Res 30:582, 1989
2. Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar REC, Fiebig HH, Double JA, Homstra HW, Pinedo HM, Workman P, Schwartsmann G: EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A:898-906, 1993
3. Bailey SM, Suggett N, Wallon MI, Workman P: Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys 22:649-653, 1992
4. Bailey SM, Friedlos F, Knox RJ, Workman P: Bioreductive activation of indoloquinone EO9: Involvement of DT-diaphorase and DNA crosslinking. Ann Oncol 3:185, 1992
5. Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE: The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem Pharmacol 44:409-412, 1992
6. Walton MI, Bibby MC, Double JA, Plumb JA, Workman P: DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 28A: 1597-1600, 1992
7. Davignon JP, Slack JA, Beijnen JH, Vezin WR, Schoemaker TJ: EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs. Eur J Cancer Oncol 24:1535-1538, 1988
8. International Conference on Harmonisation (ICH). Impurities in new drug substances. Draft 6, March 15, 1994
9. Cyr TD, Lawrence RC, Lovering EG: Survey of chlorinated hydrocarbons and other organic volatile impurities in captopril raw materials and tablets. Pharm Res 9: 1224-1226, 1992
10. United States Pharmacopeia XXII. Organic volatile impurities <467>:2927-2929, 1990
11. Residual solvents. Pharmeuropa 2:142-146, 1990
12. Oostveen EA, Speckamp WN: Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents. Tetrahedron 43:255-262, 1987
13. Speckamp WN, Oostveen EA: Indoloquinone compounds. U.S. Patent No. 5,079,257, 1992
14. Kinugawa M, Arai H, Nishikawa H, Sakaguchi A, Ogasa T, Tomioka S, Kasai M: Facile synthesis of the key intermediate of EO9 via the formation of the indole skeleton using the Nenitzescu reaction. J Chem Soc, Perkin Trans 21:2677-2678, 1995
15. De Vries JD, Winkelhorst J, Underberg WJM, Henrar REC, Beijnen JH: A systematic study on the chemical stability of the novel indoloquinone antitumour agent EO9. Int J Pharm 100:181-188, 1993
16. Taylor WG, Remers WA: Structure and stereochemistry of some 1,2-disubstitued mitosenes form solvolysis of mitomycin C and mitomycin A. J Med Chem 18:307-311, 1975
17. Beijnen JH, Lingeman H, Van Munster HA, Underberg WJM: Mitomycin antitumor agents: a review of physico-chemical and analytical properties as well as stability. J Pharm Biomed Anal 4:275-295, 1986